SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-21-115586
Filing Date
2021-04-14
Accepted
2021-04-14 09:08:00
Documents
13
Period of Report
2021-05-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A d64707ddef14a.htm DEF 14A 452650
2 GRAPHIC g64707g10o34.jpg GRAPHIC 27019
3 GRAPHIC g64707g12l21.jpg GRAPHIC 28221
4 GRAPHIC g64707g15g55.jpg GRAPHIC 26545
5 GRAPHIC g64707g20y60.jpg GRAPHIC 25210
6 GRAPHIC g64707g35z31.jpg GRAPHIC 24028
7 GRAPHIC g64707g49q08.jpg GRAPHIC 107122
8 GRAPHIC g64707g56j14.jpg GRAPHIC 255423
9 GRAPHIC g64707g57t78.jpg GRAPHIC 51485
10 GRAPHIC g64707g69o10.jpg GRAPHIC 38750
11 GRAPHIC g64707g79w22.jpg GRAPHIC 24864
12 GRAPHIC g64707g80f70.jpg GRAPHIC 170340
13 GRAPHIC g64707g91d01.jpg GRAPHIC 24921
  Complete submission text file 0001193125-21-115586.txt   1528976
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36510 | Film No.: 21824650
SIC: 2834 Pharmaceutical Preparations